Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Multiple Myeloma 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Ovarian Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Fallopian Tube Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Interferon-alpha 6Radiosurgery 4Dacarbazine 4encorafenib 3binimetinib 3aldesleukin 3Immunohistochemistry 3Gene Expression Profiling 3Filgrastim 3Cisplatin 3X-Rays 2Watchful Waiting 2Vinblastine 2Temozolomide 2Specimen Handling 2Radiotherapy 2Polymerase Chain Reaction 2Observation 2Nivolumab 2Ipilimumab 2Immunologic Techniques 2Flow Cytometry 2trametinib 1sulforaphane 1sargramostim 1romidepsin 1perifosine 1pembrolizumab 1peginterferon alfa-2b 1montanide ISA 51 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Melanoma × Dasatinib × Clear all
NCT00700882 2023-07-03

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

Eastern Cooperative Oncology Group

Phase 2 Completed
81 enrolled 9 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡